Source:http://linkedlifedata.com/resource/pubmed/id/10028075
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
1
|
| pubmed:dateCreated |
1999-6-25
|
| pubmed:abstractText |
New drugs are needed for preventing drug-resistant Plasmodium falciparum malaria. The prophylactic efficacy of azithromycin against P. falciparum in malaria-immune Kenyans was 83%. We conducted a double-blind, placebo-controlled trial to determine the prophylactic efficacy of azithromycin against multidrug-resistant P. falciparum malaria and chloroquine-resistant Plasmodium vivax malaria in Indonesian adults with limited immunity. After radical cure therapy, 300 randomized subjects received azithromycin (148 subjects, 750-mg loading dose followed by 250 mg/d), placebo (77), or doxycycline (75, 100 mg/d). The end point was slide-proven parasitemia. There were 58 P. falciparum and 29 P. vivax prophylaxis failures over 20 weeks. Using incidence rates, the protective efficacy of azithromycin relative to placebo was 71.6% (95% confidence interval [CI], 50.3-83.8) against P. falciparum malaria and 98.9% (95% CI, 93.1-99.9) against P. vivax malaria. Corresponding figures for doxycycline were 96.3% (95% CI, 85.4-99.6) and 98% (95% CI, 88.0-99.9), respectively. Daily azithromycin offered excellent protection against P. vivax malaria but modest protection against P. falciparum malaria.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
1058-4838
|
| pubmed:author |
pubmed-author:BasriHH,
pubmed-author:BermanJJ,
pubmed-author:BraitmanDD,
pubmed-author:FryauffD JDJ,
pubmed-author:GanjarAA,
pubmed-author:JonesT RTR,
pubmed-author:MurphyG SGS,
pubmed-author:OhrtCC,
pubmed-author:PicarimaHH,
pubmed-author:RichieT LTL,
pubmed-author:TangDD,
pubmed-author:TaylorW RWR,
pubmed-author:TjitraEE,
pubmed-author:WidjajaHH
|
| pubmed:issnType |
Print
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
74-81
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10028075-Adolescent,
pubmed-meshheading:10028075-Adult,
pubmed-meshheading:10028075-Animals,
pubmed-meshheading:10028075-Anti-Bacterial Agents,
pubmed-meshheading:10028075-Antibiotic Prophylaxis,
pubmed-meshheading:10028075-Antimalarials,
pubmed-meshheading:10028075-Azithromycin,
pubmed-meshheading:10028075-Double-Blind Method,
pubmed-meshheading:10028075-Doxycycline,
pubmed-meshheading:10028075-Female,
pubmed-meshheading:10028075-Humans,
pubmed-meshheading:10028075-Indonesia,
pubmed-meshheading:10028075-Malaria, Falciparum,
pubmed-meshheading:10028075-Malaria, Vivax,
pubmed-meshheading:10028075-Male,
pubmed-meshheading:10028075-Middle Aged,
pubmed-meshheading:10028075-Parasitemia,
pubmed-meshheading:10028075-Treatment Outcome
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Malaria prophylaxis using azithromycin: a double-blind, placebo-controlled trial in Irian Jaya, Indonesia.
|
| pubmed:affiliation |
U.S. Naval Medical Research Unit Number 2, Jakarta, Indonesia. Bobbo1@compuserve.com
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial
|